bxcl701
bxcl701: sourced relationships with 1 company · 2 clinical trials tracked.
bxcl701 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could bxcl701 → BTAI affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | Phase 3 |
Clinical Trial Registry Records (2)
Phase II Trial of BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Primary endpoint: Progression-free survival at 18 weeks
A Pilot Proof of Mechanism Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPPs), in Patients With Pancreatic Cancer
Primary endpoint: To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action.
Frequently asked questions
Which companies have sourced relationships with bxcl701?
bxcl701 has dated SEC/FDA relationship records for BioXcel Therapeutics, Inc..
How many clinical trials involve bxcl701?
BioSniper tracks 2 clinical trials involving bxcl701.